Evidence map›Paper›PMID 32944017›Full record

ArticleEngineering in life sciences2020

Large-scale production, purification, and function of a tumor multi-epitope vaccine: Peptibody with bFGF/VEGFA.

Ligang Zhang, Chengcheng Jiang, Xi Chen, Jiangtao Gu, Qifang Song, Hui Zhong, Sheng Xiong, Qingfeng Dong, Jin-Chen Yu, Ning Deng

Erratum issuedAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Engineering in life sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors.

Ligang ZhangGuangdong Province Engineering Research Center for Antibody Drug and Immunoassay Department of Biology Jinan University Guangzhou P. R. China.
Chengcheng JiangGuangdong Province Engineering Research Center for Antibody Drug and Immunoassay Department of Biology Jinan University Guangzhou P. R. China.
Xi ChenGuangdong Province Engineering Research Center for Antibody Drug and Immunoassay Department of Biology Jinan University Guangzhou P. R. China.
Jiangtao GuGuangdong Province Engineering Research Center for Antibody Drug and Immunoassay Department of Biology Jinan University Guangzhou P. R. China.
Qifang SongGuangdong Province Engineering Research Center for Antibody Drug and Immunoassay Department of Biology Jinan University Guangzhou P. R. China.
Hui ZhongThe Biomedicine Translational Institute in Jinan University Guangzhou P. R. China.
Sheng XiongGuangdong Jida Genetic Medicine Engineering Research Center Co. Ltd Guangzhou P. R. China.
Qingfeng DongBio-Thera Solution Co. Ltd Guangzhou P. R. China.
Jin-Chen YuBio-Thera Solution Co. Ltd Guangzhou P. R. China.
Ning DengGuangdong Province Engineering Research Center for Antibody Drug and Immunoassay Department of Biology Jinan University Guangzhou P. R. China.ORCID https://orcid.org/0000-0002-3199-8243

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In tumor tissue, basic fibroblast growth factor (bFGF) and vascular endothelial growth factor A (VEGFA) promote tumorigenesis by activating angiogenesis, but targeting single factor may produce drug resistance and compensatory angiogenesis. The Peptibody with bFGF/VEGFA was designed to simultaneously blockade these two factors. We were aiming to produce this Fc fusion protein in a large scale. The biological characterizations of Peptibody strains were identified as

Indexed as

bFGF/VEGFAfermentationPeptibodypurificationtumor angiogenesis

Identifiers

PMID32944017
PMCPMC7481771

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.